The company reading your wound care charts is not a clinical peer. It is a portfolio asset owned by private equity, paid on contingency, operating an algorithm you cannot see. This piece maps what that means for the physician at the fax machine — and what to do before it arrives in Florida.

The real story is about a payment system that was structurally broken from the start, a market that responded to those incentives exactly the way markets do, and a regulatory apparatus that was either unwilling or unable to act until the damage became impossible to ignore.

Something big is happening in wound care that most people haven’t fully articulated yet. It’s showing up in acquisition announcements, in the silence where sales reps used to be, in AR ledgers that haven’t moved in months. This is consolidation. And it’s moving faster than most expected.

The market is in the middle of a forced restructuring, and the outcome is going to look nothing like the past three years. Here’s what’s already happening, who survives, and why.

Not every graft can be perfectly matched to a wound, and that’s not new. What has changed is how those decisions are being evaluated — the rules have changed and the gap is where risk is now.

What does CMS do with the evidence question, and do the manufacturers still standing have the data required to compete in the reimbursement environment being built for 2027 and beyond?

Audit pressure has been present for years, but it is now showing up more consistently across practices and more directly inside treatment decisions. These are the consequences of what that does to the industry.

Not all Medicare audits are the same. The word "audit" covers everything from a routine documentation request to a federal fraud investigation. Here is what each type of review is, what authority governs it, and what providers can expect when it arrives.

An National Coverage Determination does not remove complexity from wound care but it does give that complexity a more stable structure. Here is where Bionavix is focused around that.

Lower pricing in wound care doesn’t reduce cost. It transfers responsibility and creates a more self-managed care system, which introduces greater risk for physicians. Here’s what that looks like.

You may believe if you build a solid documentation template — wound size, chronicity, conservative care failure, ABI, smoking cessation, all the expected fields, you’re protected. You would be wrong.

January 2026 is not just the start of a new era in wound care. It marks the moment when the economics of skin-substitutes and wound barriers are rewritten in real time. That gap between past and future is where real exposure is now. Here’s a quick primer.